Srb Corp Vertex Pharmaceuticals Inc Transaction History

Srb Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $55,566 - $66,530	162 Added 12.33%	1,476 $600,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $24,839 - $27,800	79 Added 6.4%	1,314 $462,000
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $66,275 - $75,605	-234 Reduced 15.93%	1,235 $389,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $13,430 - $15,109	47 Added 3.31%	1,469 $424,000
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $389,386 - $434,463	1,422 New	1,422 $412,000
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $719,187 - $838,310	-3,474 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $719,152 - $959,136	3,474 New	3,474 $821,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $407,272 - $547,012	-2,443 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $54,190 - $60,991	-326 Reduced 11.77%	2,443 $414,000
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $455,805 - $527,134	2,769 New	2,769 $508,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Srb Corp, based on Form 13F filings with the SEC.

Stay updated on Srb Corp with notifications on news.